Related references
Note: Only part of the references are listed.Toxicity Induced by a Bispecific T Cell-Redirecting Protein Is Mediated by Both T Cells and Myeloid Cells in Immunocompetent Mice
Claire Godbersen-Palmer et al.
JOURNAL OF IMMUNOLOGY (2020)
Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells
Lucas Ferrari de Andrade et al.
CANCER IMMUNOLOGY RESEARCH (2020)
The NKG2D axis: an emerging target in cancer immunotherapy
Mariya Lazarova et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2019)
Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients
Lin Xiao et al.
MOLECULAR THERAPY (2019)
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies
Lorraine Springuel et al.
BIODRUGS (2019)
Impairment of NKG2D-Mediated Tumor Immunity by TGF-β
Mariya Lazarova et al.
FRONTIERS IN IMMUNOLOGY (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors
Robin Parihar et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Susanne H. Baumeister et al.
CANCER IMMUNOLOGY RESEARCH (2019)
NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment
Alexandra Frazao et al.
FRONTIERS IN IMMUNOLOGY (2019)
Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway
Maite Alvarez et al.
JCI INSIGHT (2019)
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
Ye Li et al.
CELL STEM CELL (2018)
Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy
Joana M. Murad et al.
CYTOTHERAPY (2018)
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient
David A. Sallman et al.
HAEMATOLOGICA (2018)
Natural killers join the fight against cancer An antibody overcomes cancer cell immune evasion and activates natural killer cells
Adelheid Cerwenka et al.
SCIENCE (2018)
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity
Lucas Ferrari de Andrade et al.
SCIENCE (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient
David A. Sallman et al.
HAEMATOLOGICA (2018)
A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma
Wing Keung Chan et al.
CANCER IMMUNOLOGY RESEARCH (2018)
More than Decoration: Roles for Natural Killer Group 2 Member D Ligand expression by immune Cells
Andrew P. Trembath et al.
FRONTIERS IN IMMUNOLOGY (2018)
Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4
Tobias Zoeller et al.
FRONTIERS IN IMMUNOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
NK cell receptor NKG2D sets activation threshold for the NCR1 receptor early in NK cell development
Vedrana Jelencic et al.
NATURE IMMUNOLOGY (2018)
NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy
Dominik Schmiedel et al.
FRONTIERS IN IMMUNOLOGY (2018)
NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma
Tobias Weiss et al.
CANCER RESEARCH (2018)
The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma
Sam Sheppard et al.
NATURE COMMUNICATIONS (2017)
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types
Caroline Lonez et al.
BMJ OPEN (2017)
Natural Killer Group 2D Ligand Depletion Reconstitutes Natural Killer Cell Immunosurveillance of Head and Neck Squamous Cell Carcinoma
Sandra Weil et al.
FRONTIERS IN IMMUNOLOGY (2017)
Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance
Alessandra Zingoni et al.
FRONTIERS IN IMMUNOLOGY (2017)
Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice
Marie-Louise Sentman et al.
JOURNAL OF IMMUNOLOGY (2016)
Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy
Reza Ghasemi et al.
NATURE COMMUNICATIONS (2016)
TRUCKs: the fourth generation of CARs
Markus Chmielewski et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Genetics, genomics, and evolutionary biology of NKG2D ligands
Raphael Carapito et al.
IMMUNOLOGICAL REVIEWS (2015)
DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy
Katrin Toepfer et al.
JOURNAL OF IMMUNOLOGY (2015)
T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice
Heather VanSeggelen et al.
MOLECULAR THERAPY (2015)
A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection
Weiwen Deng et al.
SCIENCE (2015)
NKG2D Receptor and Its Ligands in Host Defense
Lewis L. Lanier
CANCER IMMUNOLOGY RESEARCH (2015)
The impact of glycosyl-phosphatidyl-inositol anchored MICA alleles on novel NKG2D-based therapies
Mar Vales-Gomez
FRONTIERS IN IMMUNOLOGY (2015)
Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia
A. Baragano Raneros et al.
GENES AND IMMUNITY (2015)
Effect of NKG2D ligand expression on host immune responses
Marine Champsaur et al.
IMMUNOLOGICAL REVIEWS (2015)
An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia
Julia Steinbacher et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma
Achim Rothe et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Fc-Optimized NKG2D-Fc Constructs Induce NK Cell Antibody-Dependent Cellular Cytotoxicity against Breast Cancer Cells Independently of HER2/neu Expression Status
Stefanie Raab et al.
JOURNAL OF IMMUNOLOGY (2014)
MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape
Paula Codo et al.
ONCOTARGET (2014)
Regulation of Ligands for the NKG2D Activating Receptor
David H. Raulet et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
A GPI anchor explains the unique biological features of the common NKG2D-ligand allele MICA*008
Omodele Ashiru et al.
BIOCHEMICAL JOURNAL (2013)
A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells
Yu-Hsiang Chang et al.
CANCER RESEARCH (2013)
CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma
Andre Veillette et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Chimeric NKG2D CAR-Expressing T Cell-Mediated Attack of Human Ovarian Cancer Is Enhanced by Histone Deacetylase Inhibition
De-Gang Song et al.
HUMAN GENE THERAPY (2013)
Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: Heterogeneous involvement of the a disintegrin and metalloproteases 10 and 17
Guranda Chitadze et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Mouse Tumor Vasculature Expresses NKG2D Ligands and Can Be Targeted by Chimeric NKG2D-Modified T Cells
Tong Zhang et al.
JOURNAL OF IMMUNOLOGY (2013)
The Basic Principles of Chimeric Antigen Receptor Design
Michel Sadelain et al.
CANCER DISCOVERY (2013)
Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors
Paul Spear et al.
ONCOIMMUNOLOGY (2013)
New prospects on the NKG2D/NKG2DL system for oncology
Evelyn Ullrich et al.
ONCOIMMUNOLOGY (2013)
Tumor Suppressive MicroRNAs miR-34a/c Control Cancer Cell Expression of ULBP2, a Stress-Induced Ligand of the Natural Killer Cell Receptor NKG2D
Anja Heinemann et al.
CANCER RESEARCH (2012)
RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry
Heiyoun Jung et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Chimeric Antigen Receptor T Cells Shape Myeloid Cell Function within the Tumor Microenvironment through IFN-γ and GM-CSF
Paul Spear et al.
JOURNAL OF IMMUNOLOGY (2012)
Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses
Julia Hilpert et al.
JOURNAL OF IMMUNOLOGY (2012)
Redirecting T Cells to Ewing's Sarcoma Family of Tumors by a Chimeric NKG2D Receptor Expressed by Lentiviral Transduction or mRNA Transfection
Manfred Lehner et al.
PLOS ONE (2012)
Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1
Yuk Pheel Park et al.
BLOOD (2011)
Cancer Immunotherapy Using a Bispecific NK Receptor Fusion Protein that Engages both T Cells and Tumor Cells
Tong Zhang et al.
CANCER RESEARCH (2011)
Inhibition of NKG2D expression in NK cells by cytokines secreted in response to human cytomegalovirus infection
Aura Muntasell et al.
BLOOD (2010)
Natural Killer Cell Cytotoxicity Is Suppressed by Exposure to the Human NKG2D Ligand MICA*008 That Is Shed by Tumor Cells in Exosomes
Omodele Ashiru et al.
CANCER RESEARCH (2010)
Differential Mechanisms of Shedding of the Glycosylphosphatidylinositol (GPI)-anchored NKG2D Ligands
Lola Fernandez-Messina et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Cutting Edge: The Membrane Type Matrix Metalloproteinase MMP14 Mediates Constitutive Shedding of MHC Class I Chain-Related Molecule A Independent of A Disintegrin and Metalloproteinases
Gang Liu et al.
JOURNAL OF IMMUNOLOGY (2010)
2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells
Bianca Altvater et al.
CLINICAL CANCER RESEARCH (2009)
Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha 2 domain
Mareike Wittenbrink et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
ULBP6/RAET1L is an additional human NKG2D ligand
Robert A. Eagle et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Chimeric NKG2D Expressing T Cells Eliminate Immunosuppression and Activate Immunity within the Ovarian Tumor Microenvironment
Amorette Barber et al.
JOURNAL OF IMMUNOLOGY (2009)
Proteasome Regulation of ULBP1 Transcription
James E. Butler et al.
JOURNAL OF IMMUNOLOGY (2009)
Oncogenic stress sensed by the immune system: role of natural killer cell receptors
David H. Raulet et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors
Mar Vales-Gomez et al.
CANCER RESEARCH (2008)
Tumor-associated MICA is shed by ADAM proteases
Inja Waldhauer et al.
CANCER RESEARCH (2008)
Direct and natural killer cell-mediated antitumor effects of low-dose Bortezomib in hepatocellular carcinoma
Sorin Armeanu et al.
CLINICAL CANCER RESEARCH (2008)
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy
Nadia Guerra et al.
IMMUNITY (2008)
Interaction of Monocytes with NK Cells upon Toll-Like Receptor-Induced Expression of the NKG2D Ligand MICA
Mercedes Kloss et al.
JOURNAL OF IMMUNOLOGY (2008)
NK cells and cancer immunosurveillance
I. Waldhauer et al.
ONCOGENE (2008)
Chimeric NKG2D-Modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways
Tong Zhang et al.
CANCER RESEARCH (2007)
Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis
Cristina Cerboni et al.
BLOOD (2007)
In Vivo Expression Pattern of MICA and MICB and Its Relevance to Auto-Immunity and Cancer
Stephanie Schrambach et al.
PLOS ONE (2007)
Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA
Stefan Holdenrieder et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
TGF-β and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells
Guenter Eisele et al.
BRAIN (2006)
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
EP von Strandmann et al.
BLOOD (2006)
Proteolytic release of soluble UL16-binding protein 2 from tumor cells
I Waldhauer et al.
CANCER RESEARCH (2006)
Release of MICB molecules by tumor cells: Mechanism and soluble MICB in sera of cancer patients
Helmut Rainer Salih et al.
HUMAN IMMUNOLOGY (2006)
Soluble MICA in malignant diseases
S Holdenrieder et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
IL-21 down-regulates NKG2D/DAP10 express on human NK and CD8+ T cells
SJ Burgess et al.
JOURNAL OF IMMUNOLOGY (2006)
Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion
YT Bryceson et al.
BLOOD (2006)
NKG2D-mediated activation of cytotoxic lymphocytes: Unique signaling pathways and distinct functional outcomes
Jadee L. Upshaw et al.
SEMINARS IN IMMUNOLOGY (2006)
Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy
T Zhang et al.
BLOOD (2005)
Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance
DE Oppenheim et al.
NATURE IMMUNOLOGY (2005)
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
S Gasser et al.
NATURE (2005)
Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo
K Wiemann et al.
JOURNAL OF IMMUNOLOGY (2005)
Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D Ligands by the histone deacetylase inhibitor sodium valproate
S Armeanu et al.
CANCER RESEARCH (2005)
The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure
D Garrity et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Cutting edge:: NKG2D is a costimulatory receptor for human naive CD8+ T cells
K Maasho et al.
JOURNAL OF IMMUNOLOGY (2005)
Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells
JD Coudert et al.
BLOOD (2005)
Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors
P André et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Cutting edge: Toll-like receptor signaling in macrophages induces ligands for the NKG2D receptor
JA Hamerman et al.
JOURNAL OF IMMUNOLOGY (2004)
Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease
B Meresse et al.
IMMUNITY (2004)
Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D
L Bacon et al.
JOURNAL OF IMMUNOLOGY (2004)
Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection
M Jinushi et al.
JOURNAL OF IMMUNOLOGY (2003)
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia
HR Salih et al.
BLOOD (2003)
Immune functions encoded by the natural killer gene complex
WM Yokoyama et al.
NATURE REVIEWS IMMUNOLOGY (2003)
Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors:: Consequences for the NK-mediated killing of dendritic cells
R Castriconi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein
SA Welte et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
V Groh et al.
NATURE (2002)
Cutting edge: Down-regulation of MICA on human tumors by proteolytic shedding
HR Salih et al.
JOURNAL OF IMMUNOLOGY (2002)
Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction
C Uherek et al.
BLOOD (2002)
Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition?
E Vivier et al.
CURRENT OPINION IN IMMUNOLOGY (2002)
Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining
JE Gumperz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Conformational plasticity revealed by the cocrystal structure of NKG2D and its class I MHC-like ligand ULBP3
S Radaev et al.
IMMUNITY (2001)
Cutting edge: NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment
AI Roberts et al.
JOURNAL OF IMMUNOLOGY (2001)
Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo
A Cerwenka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
A Diefenbach et al.
NATURE (2001)
Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family
A Steinle et al.
IMMUNOGENETICS (2001)
Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA
PW Li et al.
NATURE IMMUNOLOGY (2001)
Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells
V Groh et al.
NATURE IMMUNOLOGY (2001)
ULBPs, novel MHC class I-related molecules bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor
D Cosman et al.
IMMUNITY (2001)
Share Paper
